Table 3

Analysis of mOS in patients with HCC treated with ICB (n=49)

FactormOS (months)OR (95% CI)P value
Hepatitis status
 Negative14Reference
 Positive14.21.035 (0.514 to 2.085)0.9226
Stage
 B18.5Reference
 C141.032 (0.361 to 2.949)0.9530
Age
 <659.59Reference
 ≥6514.190.781 (0.395 to 1.543)0.4770
AFP marker
 <40012.6Reference
 ≥40018.90.807 (0.399 to 1.634)0.5514
ECOG
 014Reference
≥1 15.80.844 (0.391 to 1.824)0.6665
Child-Pugh score
 A515.84Reference
 A65.59
 B7 and B86.871.377 (0.696 to 2.726)0.3582
Macrovascular invasion
 Yes12.68Reference
 No9.6201.356 (0.635 to 2.898)0.4313
Extrahepatic spread
 Yes14.232Reference
 No5.6011.436 (0.685 to 3.008)0.3370
 Intratumoral total CD38+ cell proportion
 Low9.59Reference
 High19.060.463 (0.232 to 0.926) 0.0295*
 Intratumoral CD38+CD68+ macrophage density
 Low9.66Reference
 High34.430.416 (0.186 to 0.934) 0.0336*
 Intratumoral CD38CD68+ macrophage density
 Low9.59Reference
 High13.961.419 (0.723 to 2.786)0.3096
 Intratumoral CD38+CD68cells density
 Low7.85Reference
 High15.840.58 (0.297 to 1.131)0.1099
 Intratumoral CD8+ T cell density
 Low8.31Reference
 High18.530.593 (0.301 to 1.17)0.1321
 PD-L1 TPS
 <114Reference
 ≥1%18.50.815 (0.404 to 1.641)0.5662
  • *P<0.05 indicated a statistically significant difference.

  • †Staged according to the BCLC staging system.28

  • AFP, alpha-fetoprotein; ECOG, Eastern Cooperative Oncology Group; ICB, immune checkpoint blockade; mOS, median overall survival; PD-L1, programmed death-ligand 1; TPS, tumor proportion score.